Share Price and Basic Stock Data
Last Updated: December 26, 2025, 8:28 pm
| PEG Ratio | 3.37 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bafna Pharmaceuticals Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹387 Cr. The company’s stock price stood at ₹164, reflecting a price-to-earnings ratio of 36.6. Over the last fiscal year, the company reported an annual revenue of ₹146 Cr for FY 2025, with a trailing twelve months (TTM) revenue of ₹142 Cr. Revenue has shown fluctuations, peaking at ₹42.24 Cr in Q4 FY 2023 and declining to ₹28.44 Cr in Q4 FY 2024. Quarterly sales data indicates a volatile trend, with significant sales growth from ₹16.93 Cr in Q1 FY 2022 to ₹42.24 Cr in Q4 FY 2023, followed by a gradual decline. The operating profit margin (OPM) was recorded at 14.64% for FY 2025, indicating a moderate profitability level compared to industry norms. This performance suggests that while Bafna Pharmaceuticals has experienced revenue growth, it faces challenges in maintaining consistent sales figures, which may impact future financial stability.
Profitability and Efficiency Metrics
The profitability metrics of Bafna Pharmaceuticals reflect a mixed performance. The company reported a net profit of ₹9 Cr for FY 2025, translating to earnings per share (EPS) of ₹1.75. However, recent quarterly results for Q4 FY 2024 indicated a net loss of ₹0.72 Cr, raising concerns about the company’s short-term profitability. The operating profit margin fluctuated throughout the quarters, with a peak of 18.04% in Q4 FY 2023, but dropping to -7.28% in Q4 FY 2024 before recovering to 14.64% in Q1 FY 2025. Efficiency ratios such as the cash conversion cycle (CCC) stood at 88 days, indicating that the company takes a relatively long time to convert its investments in inventory and other resources into cash flows. The interest coverage ratio (ICR) of 15.48x suggests strong capacity to meet interest obligations, although the overall net profit performance raises questions about operational efficiency and cost management.
Balance Sheet Strength and Financial Ratios
Bafna Pharmaceuticals’ balance sheet indicates a cautious financial position, with total borrowings amounting to ₹32 Cr against reserves of ₹68 Cr. The company’s debt-to-equity ratio remains manageable, standing at 0.49x, suggesting a lower level of financial risk compared to industry standards. However, the price-to-book value (P/BV) ratio of -0.49x indicates that the market values the company’s equity lower than its book value, which may signal market skepticism regarding its future growth prospects. The return on equity (ROE) was recorded at 7.69%, while the return on capital employed (ROCE) was 8.34%, both of which are relatively low when compared to typical benchmarks in the pharmaceuticals sector. The company’s total assets were reported at ₹153 Cr, while total liabilities stood at ₹148 Cr, indicating a tight balance between assets and liabilities. This financial structure highlights potential vulnerabilities in capital management and operational efficiency, necessitating a focus on improving profitability to enhance shareholder value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bafna Pharmaceuticals reflects a strong promoter presence, with promoters holding 75% of the equity as of March 2025. This significant stake demonstrates a commitment to the company’s long-term growth, although it may also limit public participation in governance. Foreign institutional investors (FIIs) have increased their stake to 9.34%, indicating growing confidence from external investors. Conversely, domestic institutional investors (DIIs) have no reported stake, which could imply a lack of interest or confidence among institutional players. The total number of shareholders has seen a slight increase, reaching 7,572 in September 2025, which may indicate a growing interest in the stock despite its recent volatility. However, the declining public shareholding from 90.01% in December 2022 to 15.66% in September 2025 raises concerns about liquidity and market perception. This dynamic in the shareholding pattern reflects a critical balance between promoter control and the need for broader investor participation to enhance market confidence.
Outlook, Risks, and Final Insight
The outlook for Bafna Pharmaceuticals hinges on its ability to stabilize revenue and profitability. Key strengths include a strong interest coverage ratio and a solid promoter holding, which can support strategic initiatives. However, risks remain, including fluctuating sales, a high cash conversion cycle, and low profitability margins, which could affect operational viability. The recent decline in quarterly net profits and the negative OPM in Q4 FY 2024 raise alarms about the company’s financial health. If the company can effectively manage operational costs and enhance sales consistency, there is potential for recovery. Conversely, failure to address these challenges may lead to further declines in investor confidence and market valuation. The company’s ability to navigate these risks while leveraging its strengths will be crucial in determining its future trajectory in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,816 Cr. | 443 | 479/192 | 99.7 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,100.18 Cr | 1,149.90 | 52.73 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.93 | 21.96 | 34.22 | 42.24 | 41.95 | 40.68 | 28.44 | 41.40 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 |
| Expenses | 15.27 | 19.42 | 31.18 | 34.62 | 35.66 | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 |
| Operating Profit | 1.66 | 2.54 | 3.04 | 7.62 | 6.29 | 4.01 | -2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 |
| OPM % | 9.81% | 11.57% | 8.88% | 18.04% | 14.99% | 9.86% | -7.28% | 6.98% | 3.63% | 9.40% | 9.22% | 7.96% | 14.64% |
| Other Income | 1.30 | 0.64 | 1.93 | 0.26 | 1.87 | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.18 | -0.76 | 0.60 |
| Interest | 0.31 | 0.45 | 0.58 | 0.70 | 0.60 | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 |
| Depreciation | 1.29 | 1.12 | 1.40 | 1.53 | 1.21 | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 |
| Profit before tax | 1.36 | 1.61 | 2.99 | 5.65 | 6.35 | 2.49 | -2.94 | 1.46 | -0.72 | 2.61 | 0.94 | 1.31 | 3.39 |
| Tax % | -0.00% | -0.00% | -0.00% | 4.96% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | 1.36 | 1.61 | 3.00 | 5.37 | 6.35 | 2.48 | -2.94 | 1.46 | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 |
| EPS in Rs | 0.57 | 0.68 | 1.27 | 2.27 | 2.68 | 1.05 | -1.24 | 0.62 | -0.30 | 1.11 | 0.40 | 0.55 | 1.43 |
Last Updated: August 20, 2025, 1:15 pm
Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 34.62 Cr.. The value appears to be declining and may need further review. It has decreased from 39.06 Cr. (Mar 2025) to 34.62 Cr., marking a decrease of 4.44 Cr..
- For Expenses, as of Jun 2025, the value is 29.55 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.95 Cr. (Mar 2025) to 29.55 Cr., marking a decrease of 6.40 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 3.11 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 1.96 Cr..
- For OPM %, as of Jun 2025, the value is 14.64%. The value appears strong and on an upward trend. It has increased from 7.96% (Mar 2025) to 14.64%, marking an increase of 6.68%.
- For Other Income, as of Jun 2025, the value is 0.60 Cr.. The value appears strong and on an upward trend. It has increased from -0.76 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 1.36 Cr..
- For Interest, as of Jun 2025, the value is 0.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Mar 2025) to 0.91 Cr., marking an increase of 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.22 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 1.15 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.43. The value appears strong and on an upward trend. It has increased from 0.55 (Mar 2025) to 1.43, marking an increase of 0.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:36 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 142 |
| Expenses | 156 | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 127 |
| Operating Profit | 21 | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 11 | 16 |
| OPM % | 12% | -16% | 3% | -8% | -77% | -30% | 3% | 14% | 14% | 14% | 7% | 8% | 11% |
| Other Income | 1 | 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 1 | 1 |
| Interest | 12 | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 8 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 2 | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 4 | 9 |
| Tax % | 40% | -0% | -3% | -4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | 0% | |
| Net Profit | 1 | 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 4 | 9 |
| EPS in Rs | 0.72 | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 3.70 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -300.00% | -50.00% | 11.11% | -25.00% | -25.00% | 124.00% | -16.67% | 120.00% | -36.36% | -42.86% |
| Change in YoY Net Profit Growth (%) | 0.00% | -800.00% | 250.00% | 61.11% | -36.11% | 0.00% | 149.00% | -140.67% | 136.67% | -156.36% | -6.49% |
Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 28% |
| 3 Years: | 20% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 40% |
| 3 Years: | -5% |
| TTM: | 1498% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 34% |
| 3 Years: | -4% |
| 1 Year: | 25% |
| Return on Equity | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 12:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 50 | 53 | 41 | 26 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 61 | 68 |
| Borrowings | 99 | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 32 |
| Other Liabilities | 54 | 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 37 |
| Total Liabilities | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
| Fixed Assets | 63 | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 65 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 7 | 15 |
| Investments | 1 | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 158 | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 81 |
| Total Assets | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 7.00 Cr..
- For Borrowings, as of Sep 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 28.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be improving (decreasing). It has decreased from 40.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 161.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 6.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 6.00 Cr..
- For Total Assets, as of Sep 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
Notably, the Reserves (68.00 Cr.) exceed the Borrowings (32.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -78.00 | -80.00 | -77.00 | -87.00 | -82.00 | -59.00 | -2.00 | -5.00 | 1.00 | -7.00 | -13.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192 | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 |
| Inventory Days | 78 | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 |
| Days Payable | 116 | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 |
| Cash Conversion Cycle | 155 | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 | 88 |
| Working Capital Days | 41 | 56 | 125 | -36 | -108 | -210 | 89 | 121 | 123 | 104 | 92 | 74 |
| ROCE % | 9% | -13% | -0% | -6% | -35% | -21% | -3% | 10% | 11% | 16% | 9% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Diluted EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Cash EPS (Rs.) | -89.52 | -6.29 | -5.47 | -8.17 | -5.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Revenue From Operations / Share (Rs.) | 179.54 | 18.33 | 19.94 | 34.82 | 45.73 |
| PBDIT / Share (Rs.) | 6.25 | -5.36 | -1.61 | -2.50 | 1.34 |
| PBIT / Share (Rs.) | -7.56 | -6.83 | -3.29 | -4.76 | -1.27 |
| PBT / Share (Rs.) | -103.32 | -7.30 | -6.22 | -10.91 | -8.21 |
| Net Profit / Share (Rs.) | -103.32 | -7.76 | -7.15 | -10.43 | -8.12 |
| NP After MI And SOA / Share (Rs.) | -104.54 | -7.98 | -7.07 | -10.23 | -7.52 |
| PBDIT Margin (%) | 3.48 | -29.26 | -8.05 | -7.18 | 2.92 |
| PBIT Margin (%) | -4.20 | -37.28 | -16.47 | -13.68 | -2.76 |
| PBT Margin (%) | -57.54 | -39.86 | -31.19 | -31.34 | -17.95 |
| Net Profit Margin (%) | -57.54 | -42.32 | -35.84 | -29.95 | -17.74 |
| NP After MI And SOA Margin (%) | -58.22 | -43.52 | -35.48 | -29.38 | -16.44 |
| Return on Networth / Equity (%) | 0.00 | -99.01 | -44.12 | -44.73 | -24.28 |
| Return on Capital Employeed (%) | -3.29 | -33.22 | -9.90 | -9.17 | -2.41 |
| Return On Assets (%) | -34.67 | -15.79 | -12.09 | -10.70 | -7.27 |
| Long Term Debt / Equity (X) | -0.71 | 1.21 | 0.61 | 0.91 | 0.60 |
| Total Debt / Equity (X) | -0.71 | 2.43 | 1.23 | 1.93 | 1.39 |
| Asset Turnover Ratio (%) | 0.44 | 0.33 | 0.30 | 0.36 | 0.44 |
| Current Ratio (X) | 2.11 | 0.68 | 0.81 | 0.94 | 1.29 |
| Quick Ratio (X) | 1.44 | 0.55 | 0.63 | 0.74 | 1.11 |
| Inventory Turnover Ratio (X) | 2.24 | 2.66 | 1.55 | 0.89 | 0.97 |
| Interest Coverage Ratio (X) | 15.48 | -5.97 | -0.54 | -0.40 | 0.19 |
| Interest Coverage Ratio (Post Tax) (X) | -18.72 | -8.10 | -1.44 | -0.69 | -0.16 |
| Enterprise Value (Cr.) | -3.29 | 69.21 | 109.10 | 134.30 | 133.55 |
| EV / Net Operating Revenue (X) | -0.07 | 1.60 | 2.31 | 2.07 | 1.57 |
| EV / EBITDA (X) | -2.22 | -5.45 | -28.71 | -28.76 | 53.52 |
| MarketCap / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| Price / BV (X) | -0.49 | 1.36 | 1.75 | 1.29 | 0.96 |
| Price / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| EarningsYield | -11.80 | -0.72 | -0.25 | -0.34 | -0.25 |
After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
- For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
- For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
- For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
- For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
- For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
- For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
- For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
- For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
- For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
- For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
- For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
- For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
- For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
- For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
- For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
- For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
- For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
- For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
- For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
- For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
- For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
- For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
- Net Profit Margin: -57.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -3.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -18.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.44
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.6 (Industry average Stock P/E: 52.73)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -57.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bafna Towers, Chennai (Madras) Tamil Nadu 600001 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. S Hemalatha | Whole Time Director |
| Mr. Vinayak Dinesh Dendukuri | Whole Time Director |
| Mr. Upendar Mekala Reddy | Non Exe.Non Ind.Director |
| Mrs. Akila C Raju | Non Exe.Non Ind.Director |
| Ms. R Chitra | Ind. Non-Executive Director |
| Mr. Navin Kumar | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's intrinsic value (as of 26 December 2025) is 88.65 which is 45.95% lower the current market price of 164.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 387 Cr. market cap, FY2025-2026 high/low of 205/67.8, reserves of ₹68 Cr, and liabilities of 161 Cr.
What is the Market Cap of Bafna Pharmaceuticals Ltd?
The Market Cap of Bafna Pharmaceuticals Ltd is 387 Cr..
What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 26 December 2025?
The current stock price of Bafna Pharmaceuticals Ltd as on 26 December 2025 is 164.
What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bafna Pharmaceuticals Ltd stocks is 205/67.8.
What is the Stock P/E of Bafna Pharmaceuticals Ltd?
The Stock P/E of Bafna Pharmaceuticals Ltd is 36.6.
What is the Book Value of Bafna Pharmaceuticals Ltd?
The Book Value of Bafna Pharmaceuticals Ltd is 38.6.
What is the Dividend Yield of Bafna Pharmaceuticals Ltd?
The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Bafna Pharmaceuticals Ltd?
The ROCE of Bafna Pharmaceuticals Ltd is 8.34 %.
What is the ROE of Bafna Pharmaceuticals Ltd?
The ROE of Bafna Pharmaceuticals Ltd is 7.69 %.
What is the Face Value of Bafna Pharmaceuticals Ltd?
The Face Value of Bafna Pharmaceuticals Ltd is 10.0.